Public Interest Litigation in Delhi High Court seeks to ban on sex-selective surgeries
By Amiya Kumar Kushwaha,
Asian News International
| 08. 16. 2021
Photo by Sadasiv Swain on Flickr
A public interest litigation (PIL) was filed in the Delhi High Court seeking to declare a ban on medically unnecessary, sex-selective surgeries on intersex infants and children except in cases of life-threatening situations in the national capital.
The public interest litigation was filed by Srishti Madurai Educational Research Foundation through advocates Robin Raju, Yash Prakash and Deepa Joseph.
The petitioner organisation claimed to be at the forefront in spreading awareness about the necessity to ban sex-selective surgeries on infants with intersex traits.
The petitioner said that the Delhi Commission for Protection of Child Rights (DCPCR) in January 2021 had given a considered opinion that the Respondent Delhi government and its state Ministry of Health and Family Welfare should declare a ban on medically unnecessary, sex-selective surgeries on intersex infants and children except in cases of life-threatening situations but no decision has been taken on the opinion of DCPCR.
"That the issue of sex-selective surgeries or medically unnecessary normalizing surgeries has a long lasting drastic psychological impact on the minds of intersex people and deters...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...